Form 4: TG Therapeutics Director Daniel Hume Receives Significant Restricted Stock Grant

TG Therapeutics, Inc. Director Daniel Hume was granted 14,718 restricted shares of common stock on June 12, 2025, increasing his total beneficial ownership to 192,748 shares.

Summary

• Daniel Hume, a Director of TG Therapeutics, Inc. (TGTX), acquired 14,718 shares of common stock.
• The acquisition was a grant of restricted shares, meaning they were issued at a price of $0.
• These restricted shares are scheduled to vest on June 12, 2026.
• Following this transaction, Daniel Hume's total beneficial ownership in TG Therapeutics, Inc. stands at 192,748 shares of common stock.
• The reported transaction date was June 12, 2025, and the filing date was June 16, 2025.

Sentiment

Score: 7

Explanation: The grant of restricted shares to a director is generally a positive signal, indicating alignment of interests and confidence in the company's future. While it's a routine compensation event, it contributes to insider ownership, which is often viewed favorably.

Positives

• The grant of restricted shares to a director aligns the director's long-term interests with those of shareholders, as the shares vest over time and their value is tied to the company's stock performance.
• An increase in a director's beneficial ownership can signal continued confidence in the company's future prospects and strategic direction.

Future Outlook

This Form 4 filing reports an individual insider transaction and does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic outlook.

Industry Context

This Form 4 filing details a routine insider transaction involving a restricted stock grant to a director. Such grants are a common component of executive and director compensation packages across various industries, including biotechnology and pharmaceuticals, serving to align the interests of company leadership with long-term shareholder value. This specific filing does not provide broader industry context or trends.

Comparison to Industry Standards

• This Form 4 filing reports a specific insider compensation event and does not provide financial or operational data for direct comparison to industry-specific benchmarks or competitor results.
• Restricted stock grants, like the one received by Daniel Hume, are a standard and widely adopted form of equity compensation for directors and executives in publicly traded companies across diverse sectors, including those comparable to TG Therapeutics in the biotechnology and pharmaceutical industries. This practice is consistent with global corporate governance standards aimed at aligning management incentives with shareholder interests.

Corporate Governance

Related Party Transactions

• The grant of 14,718 restricted shares to Daniel Hume, a Director of TG Therapeutics, Inc., constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The grant of restricted shares to a director aligns the director's long-term interests with those of shareholders, potentially fostering better governance and strategic decisions aimed at increasing share value.
• Employees: This specific filing, detailing a director's compensation, does not indicate any direct impact on the broader employee base.

Next Steps

• The 14,718 restricted shares granted to Daniel Hume are scheduled to vest on June 12, 2026.

Key Dates

Keywords

TG Therapeutics, TGTX, Form 4, Insider Transaction, Restricted Stock Grant, Director Compensation, Share Ownership, Daniel Hume